{Reference Type}: Journal Article
{Title}: Diagnostic and prognostic performance of CSF α-synuclein in prion disease in the context of rapidly progressive dementia.
{Author}: Mastrangelo A;Baiardi S;Zenesini C;Poleggi A;Mammana A;Polischi B;Ladogana A;Capellari S;Parchi P;
{Journal}: Alzheimers Dement (Amst)
{Volume}: 13
{Issue}: 1
{Year}: 2021
暂无{DOI}: 10.1002/dad2.12214
{Abstract}: <B>BACKGROUND: </B>Surrogate cerebrospinal fluid (CSF) biomarkers of neurodegeneration still have a central role in the first-line screening of patients with suspected Creutzfeldt-Jakob disease (CJD). Recently, CSF α-synuclein, a marker of synaptic damage, showed a close to optimal performance in distinguishing between CJD and other neurodegenerative dementias.<BR><B>METHODS: </B>We evaluated the diagnostic value of CSF α-synuclein in patients with prion disease, non-prion rapidly progressive dementias, and non-neurodegenerative controls. Additionally, we studied its distribution across the different prion disease subtypes and evaluated its association with survival.<BR><B>RESULTS: </B>CSF α-synuclein levels were significantly higher in patients with prion disease than in the other groups but showed a lower diagnostic value than CSF total tau or 14-3-3. Moreover, CSF α-synuclein was significantly associated with survival in the whole prion cohort and the most frequent clinicopathological subtypes.<BR><B>CONCLUSIONS: </B>In the clinical setting, CSF α-synuclein does not exceed the diagnostic performance of currently used surrogate markers, but it might constitute a robust prognostic indicator.